Curis Lifesciences Reports Revenue Growth and Expands Portfolio, Enters Nigeria JV
Curis Lifesciences reported a 22.25% year-on-year revenue increase to INR 34.12 crore and a 52.84% half-on-half rise in profit after tax to INR 4.14 crore for H1 FY27. EBITDA grew 20.66% half-on-half with margin expansion. The company, through its 51%-owned subsidiary Uninova Lifesciences, is expanding its domestic branded pharmaceutical portfolio with plans to launch more products. Curis also entered a joint venture in Nigeria, holding a 49.5% stake to expand internationally.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 43/100.
Outlets measured: thetribune, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 16 Nov, 04:53 am. Other outlets followed.
